We started up our protein–protein interaction technology development activities in the mid 2000s and our research activities in the late 2000s. From the late 2010s we are also a research service provider.
We are specialized in developing yeast two-hybrid system assays that can be used to attempt to confirm protein–protein interactions (PPIs) and to map protein–protein interaction domains (PPIDs). From PPID information candidate peptide protein–protein interaction inhibitors can be derived. Short linear peptides with PPI inhibitory activity have many applications in research and using them can provide new insights, what can lead to the development of new medicine.